Three new candidate drugs are being tested in the latest phase of global Solidarity clinical trials to find effective treatments against COVID-19, the World Health Organization (WHO) announced on Wednesday. The therapies — artesunate, imatinib and infliximab — will be tested on hospitalized COVID-19 patients in 52 countries under the Solidarity PLUS programme. There have been more than 203 million cases of the disease recorded globally as of Wednesday, according to WHO data. The world hit the 200-million mark last week, just six months after cases passed 100 million. Speaking during a press conference in Geneva, agency chief Tedros Adhanom
